StemX Bio's revolutionary human in vitro 3D pancreatic model will completely transform the area of diabetes drug discovery. This innovative approach directly addresses the critical unmet need within the diabetes research community for more accurate and physiologically relevant in vitro models. With over 537 million adults diagnosed with diabetes in 2021 and projections indicating a rise to 783 million by 2045, the urgency for advanced research tools has never been more apparent. In the early stages of drug development of new diabetes treatments, researchers mostly use simple 2D cancer cell cultures or animals. These methods don't closely mimic human biology, which can lead to false negatives and false positives. Therefore, there is a clear need for developing suitable in vitro screening methods with improved predictive value that would reduce the drug screening costs.

StemX Bio is committed to addressing the limitations of 2D cancer cultures and animal models in the early drug discovery phases by offering 3D models, developed through a fully chemical, animal free process from human induced Pluripotent stem cells. Our 3D pancreatic model is a meticulously designed representation of the human pancreas, incorporating all relevant cell types (α, β, and δ cells) to ensure unparalleled physiological relevance and predictive value. Designed for high-throughput screening, these microtissues will be available in 96 and 384 well formats as a ready-to-use product, greatly streamlining drug testing workflows and enhancing the efficiency and reliability of diabetes research. This innovation not only facilitates a more accurate understanding of diabetes pathogenesis but also significantly reduces the reliance on animal testing and the associated ethical concerns.

Looking to the future, StemX Bio aims to lead the way in 3D modelling and biotechnological solutions, starting with our pancreatic model. Our differentiation protocol is ideally suited for other endodermal tissues, as by minor tweaking, we plan expand our product line into other endodermal tissues,

In the competitive landscape, our model stands out by offering a physiologically relevant, reliable, and animal-free alternative to the current cell-based assays. This competitive advantage is underpinned by our technology's scalability, cost-effectiveness, and the ethical benefits of eliminating animal testing.

Our financial roadmap outlines a three phased development plan and market introduction strategy, culminating in a breaking even by 2027. Our initial investment requirement of 370,000 EUR will cover the first development phases by 2026, where we aim to finalise the assay transfer and compounds validation.

At the helm of StemX Bio are CEO, Jane Spirkoski, and CSO/CTO, Elena Naumovska. Jane brings over nine years of extensive experience in process development and project management within the biotech and pharma sectors, ensuring the company's strategic and operational excellence. Elena, with her 15 years of expertise in stem cell differentiation, cell modelling, and regenerative medicine, spearheads the scientific innovation that underpins our 3D pancreatic model.

In conclusion, StemX Bio's human in-vitro 3D pancreatic model represents a pivotal advancement in diabetes research and drug discovery. Our commitment to innovation, combined with a clear understanding of the market needs and competitive landscape, positions us to make a meaningful impact in the fight against diabetes.

Jane Spirkoski
Elena Naumovska
Startup activities

Proefdiervrij Venture Challenge 2024